NEW YORK — A leading premium chocolate manufacturer, known for its artisanal bonbons and existential dread-inducing price tags, announced a strategic pivot today, rebranding its single-serve offerings as 'Emotional Support Truffles' for the burgeoning GLP-1 weight-loss drug market. The move comes after internal data revealed a surprising trend: users of semaglutide and tirzepatide are still buying high-end chocolate, but in dramatically reduced quantities.

“We initially panicked, envisioning a future devoid of spontaneous chocolate binges,” admitted CEO Bartholomew 'Barty' Fudge, during a press conference held in a room scented with cacao nibs. “But what we found was a new consumer: one who can actually stop at one square. Or, in our case, one exquisitely crafted, gold-dusted orb of pure, unadulterated self-care.”

The company's new marketing campaign features serene-looking individuals delicately unwrapping a single truffle, often accompanied by a caption like, 'Because some cravings are spiritual, not physiological.' Dr. Evelyn Sprinkles, a fictional behavioral economist commissioned for the campaign, added, “It’s about reclaiming the ritual. Before, it was a race to the bottom of the box. Now, it’s a mindful journey to the center of a ganache.”

Industry analysts predict other luxury food brands will soon follow, with 'Therapeutic Charcuterie Boards' and 'Conscious Consumption Caviar' expected to hit shelves by Q3.